Capital Flow Monitor · Sponsors · CIK 1972912
Crossbow Therapeutics, Inc.
1030 Massachusetts Ave, Suite 210, Cambridge, MA, 02138 · 860-501-1600
Biotechnology · Corporation· inc. DELAWARE true 2021
Fit score
—
Offering
$80.0M
Sold
$30.3M
% sold
37.8%
Investors
17
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2025-09-30 | D ·current | 506(b) | $80.0M | $30.3M | 37.8% | 17 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
-
Briggs Morrison — Executive Officer / Director / Promoter, Cambridge, MA
1 other raise
- CHARM Therapeutics Inc. $17.3M of $80.1M · 21.6%
-
Todd Foley — Director, Cambridge, MA
1 other raise
- MOAT BIOTECHNOLOGY Corp $26K of $15.6M · 0.2%
-
Alexandra Cantley — Director, Cambridge, MA
3 other raises
- Auron Therapeutics, Inc. $27.3M of $42.3M · 64.5%
- Polaris Partners XI, L.P. $0 of $500.0M · 0.0%
- Cirrus Therapeutics, Inc. $6.7M of $15.7M · 42.7%
- Irena Melnikova — Director, Cambridge, MA
-
Charles Baum — Director, Cambridge, MA
1 other raise
- Terremoto Biosciences, Inc. $40.7M of $108.6M · 37.5%
- Sakae Asanuma — Director, Cambridge, MA
-
Alon Lazarus — Director, Cambridge, MA
1 other raise
- Reunion Neuroscience, Inc. $119.9M of $119.9M · 100.0%
- Dmitri Wiederschain — Executive Officer, Cambridge, MA
- Alexander Nolte — Executive Officer, Cambridge, MA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.